Open Label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetic Characteristics of Febuxostat Between TMX-67 40mg 2 Tablets and Feburic 80mg 1 Tablet in Healthy Male Volunteers
Latest Information Update: 14 Jan 2020
At a glance
- Drugs Febuxostat (Primary)
- Indications Gout; Hyperuricaemia; Tumour lysis syndrome
- Focus Pharmacokinetics
- Sponsors SK Chemicals
- 31 Jan 2019 Last check against ClinicalTrials.gov: US National Institutes of Health
- 30 Mar 2012 New trial record